Time-dependent changes in gene expression induced by secreted amyloid precursor protein-alpha in the rat hippocampus

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Ryan, Margaret M ^a,b   Morris, Gary P ^a,b,c   Mockett, Bruce G ^a   Bourne, Katie ^a,b   Abraham, Wickliffe C ^a   Tate, Warren P ^a,b   Williams, Joanna M ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Hippocampus; Immediate early genes; Ingenuity pathway analysis; Microarray; MicroRNA; Neuroprotection; NF B; Organotypic slice cultures; Secreted amyloid precursor protein alpha

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MICRORNA; N METHYL DEXTRO ASPARTIC ACID; PHOSPHATE BUFFERED SALINE; RECOMBINANT AMYLOID PRECURSOR PROTEIN ALPHA; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARC GENE; ARTICLE; BRAIN SLICE; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN; CONTROLLED STUDY; DOWN REGULATION; EGR1 GENE; EGR2 GENE; FOS GENE; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HIPPOCAMPUS; IMMEDIATE EARLY GENE; INFLAMMATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN SECRETION; RAT; TIME SERIES ANALYSIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOPTOSIS; CELL SURVIVAL; FEMALE; HEK293 CELLS; HIPPOCAMPUS; HUMANS; INFLAMMATION; MALE; N-METHYLASPARTATE; NEUROGENESIS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

RATTUS;

EID: 84878512032     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-376     Document Type: Article

References (97)

1. Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, Bourgeat P, Salvado O, Bedo J, Hutton CA, et al. Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 2010, 30(18):6315-6322. 10.1523/JNEUROSCI.5180-09.2010, 20445057.
2. Moghekar A, Rao S, Li M, Ruben D, Mammen A, Tang X, O'Brien RJ. Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro. J Biol Chem 2011, 286(18):15989-15997. 10.1074/jbc.M110.191262, 3091208, 21454701.
3. Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 2003, 70(1):1-32. 10.1016/S0301-0082(03)00089-3, 12927332.
4. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985, 82(12):4245-4249. 10.1073/pnas.82.12.4245, 397973, 3159021.
5. Obregon D, Hou H, Deng J, Giunta B, Tian J, Darlington D, Shahaduzzaman M, Zhu Y, Mori T, Mattson MP, et al. Soluble amyloid precursor protein-alpha modulates beta-secretase activity and amyloid-beta generation. Nat Commun 2012, 3:777. 3520614, 22491325.
6. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993, 10(2):243-254. 10.1016/0896-6273(93)90315-I, 8094963.
7. Thornton E, Vink R, Blumbergs PC, Van Den Heuvel C. Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res 2006, 1094(1):38-46. 10.1016/j.brainres.2006.03.107, 16697978.
8. Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 1992, 9(1):129-137. 10.1016/0896-6273(92)90228-6, 1632967.
9. Ninomiya H, Roch JM, Jin LW, Saitoh T. Secreted form of amyloid beta/A4 protein precursor (APP) binds to two distinct APP binding sites on rat B103 neuron-like cells through two different domains, but only one site is involved in neuritotropic activity. J Neurochem 1994, 63(2):495-500.
10. Baratchi S, Evans J, Tate WP, Abraham WC, Connor B. Secreted amyloid precursor proteins promote proliferation and glial differentiation of adult hippocampal neural progenitor cells. Hippocampus 2012, 22(7):1517-1527. 10.1002/hipo.20988, 22147523.
11. Porayette P, Gallego MJ, Kaltcheva MM, Bowen RL, Vadakkadath Meethal S, Atwood CS. Differential processing of amyloid-beta precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells. J Biol Chem 2009, 284(35):23806-23817. 10.1074/jbc.M109.026328, 2749153, 19542221.
12. Caille I, Allinquant B, Dupont E, Bouillot C, Langer A, Muller U, Prochiantz A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 2004, 131(9):2173-2181. 10.1242/dev.01103, 15073156.
13. Bour A, Little S, Dodart JC, Kelche C, Mathis C. A secreted form of the beta-amyloid precursor protein (sAPP695) improves spatial recognition memory in OF1 mice. Neurobiol Learn Mem 2004, 81(1):27-38. 10.1016/S1074-7427(03)00071-6, 14670356.
14. Ishida A, Furukawa K, Keller JN, Mattson MP. Secreted form of beta-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices. NeuroReport 1997, 8(9-10):2133-2137.
15. Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 1998, 95(21):12683-12688. 10.1073/pnas.95.21.12683, 22891, 9770546.
16. Taylor CJ, Ireland DR, Ballagh I, Bourne K, Marechal NM, Turner PR, Bilkey DK, Tate WP, Abraham WC. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol Dis 2008, 31(2):250-260. 10.1016/j.nbd.2008.04.011, 18585048.
17. Claasen AM, Guevremont D, Mason-Parker SE, Bourne K, Tate WP, Abraham WC, Williams JM. Secreted amyloid precursor protein-alpha upregulates synaptic protein synthesis by a protein kinase G-dependent mechanism. Neurosci Lett 2009, 460(1):92-96. 10.1016/j.neulet.2009.05.040, 19463893.
18. Barger SW, Mattson MP. The secreted form of the Alzheimer's β-amyloid precursor protein stimulates a membrane-associated guanylate cyclase. Biochem J 1995, 311(1):45-47. 1136117, 7575479.
19. Barger SW, Fiscus RR, Ruth P, Hofmann F, Mattson MP. Role of cyclic GMP in the regulation of neuronal calcium and survival by secreted forms of beta-amyloid precursor. J Neurochem 1995, 64(5):2087-2096.
20. Cheng G, Yu Z, Zhou D, Mattson MP. Phosphatidylinositol-3-kinase-Akt kinase and p42/p44 mitogen-activated protein kinases mediate neurotrophic and excitoprotective actions of a secreted form of amyloid precursor protein. Exp Neurol 2002, 175(2):407-414. 10.1006/exnr.2002.7920, 12061870.
21. Gakhar-Koppole N, Hundeshagen P, Mandl C, Weyer SW, Allinquant B, Muller U, Ciccolini F. Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway. Eur J Neurosci 2008, 28(5):871-882. 10.1111/j.1460-9568.2008.06398.x, 18717733.
22. Chasseigneaux S, Dinc L, Rose C, Chabret C, Coulpier F, Topilko P, Mauger G, Allinquant B. Secreted amyloid precursor protein beta and secreted amyloid precursor protein alpha induce axon outgrowth in vitro through Egr1 signaling pathway. PLoS One 2011, 6(1):e16301. 10.1371/journal.pone.0016301, 3029320, 21298006.
23. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 2004, 24(35):7707-7717. 10.1523/JNEUROSCI.2211-04.2004, 15342738.
24. Aydin D, Filippov MA, Tschape JA, Gretz N, Prinz M, Eils R, Brors B, Muller UC. Comparative transcriptome profiling of amyloid precursor protein family members in the adult cortex. BMC Genomics 2011, 12:160. 10.1186/1471-2164-12-160, 3080314, 21435241.
25. Turner PR, Bourne K, Garama D, Carne A, Abraham WC, Tate WP. Production, purification and functional validation of human secreted amyloid precursor proteins for use as neuropharmacological reagents. J Neurosci Methods 2007, 164(1):68-74. 10.1016/j.jneumeth.2007.04.001, 17537517.
26. Sinor JD, Du S, Venneti S, Blitzblau RC, Leszkiewicz DN, Rosenberg PA, Aizenman E. NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro. J Neurosci 2000, 20(23):8831-8837.
27. Soverchia L, Ubaldi M, Leonardi-Essmann F, Ciccocioppo R, Hardiman G. Microarrays-the challenge of preparing brain tissue samples. Addict Biol 2005, 10(1):5-13. 10.1080/13556210412331327803, 15849014.
28. Prinzen C, Trumbach D, Wurst W, Endres K, Postina R, Fahrenholz F. Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice. BMC Genomics 2009, 10:66. 10.1186/1471-2164-10-66, 2647556, 19196476.
29. Ryan MM, Mason-Parker SE, Tate WP, Abraham WC, Williams JM. Rapidly induced gene networks following induction of long-term potentiation at perforant path synapses in vivo. Hippocampus 2011, 21(5):541-553. 10.1002/hipo.20770, 20108223.
30. Ryan MM, Ryan B, Kyrke-Smith M, Logan B, Tate WP, Abraham WC, Williams JM. Temporal profiling of gene networks associated with the late phase of long-term potentiation in vivo. PLoS One 2012, 7(7):e40538. 10.1371/journal.pone.0040538, 3393663, 22802965.
31. Tian L, McClafferty H, Knaus HG, Ruth P, Shipston MJ. Distinct acyl protein transferases and thioesterases control surface expression of calcium-activated potassium channels. J Biol Chem 2012, 287(18):14718-14725. 10.1074/jbc.M111.335547, 3340283, 22399288.
32. Fukata Y, Fukata M. Protein palmitoylation in neuronal development and synaptic plasticity. Nat Rev Neurosci 2010, 11(3):161-175.
33. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2):215-233. 10.1016/j.cell.2009.01.002, 19167326.
34. Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Camma C, Lio D, Caruso C. Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. Brain Res Rev 2009, 61(2):60-68. 10.1016/j.brainresrev.2009.05.001, 19445962.
35. Malinin NL, Wright S, Seubert P, Schenk D, Griswold-Prenner I. Amyloid-beta neurotoxicity is mediated by FISH adapter protein and ADAM12 metalloprotease activity. Proc Natl Acad Sci U S A 2005, 102(8):3058-3063. 10.1073/pnas.0408237102, 549444, 15710903.
36. Le Y, Gong W, Tiffany HL, Tumanov A, Nedospasov S, Shen W, Dunlop NM, Gao JL, Murphy PM, Oppenheim JJ, et al. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci 2001, 21(2):RC123.
37. Butterfield DA, Hardas SS, Lange ML. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration. J Alzheimers Dis 2010, 20(2):369-393. 2922983, 20164570.
38. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 2008, 14(10):1097-1105. 10.1038/nm.1868, 2789841, 18806802.
39. Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MP. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci U S A 1995, 92(20):9328-9332. 10.1073/pnas.92.20.9328, 40978, 7568127.
40. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A 1994, 91(18):8368-8372. 10.1073/pnas.91.18.8368, 44607, 8078889.
41. Liao Y, Guan ZZ, Ravid R. [Changes of nuclear factor and inflammatory chemotactic factors in brain of patients with Alzheimer's disease]. Zhonghua Bing Li Xue Za Zhi 2011, 40(9):585-589.
42. Lu W, Mi R, Tang H, Liu S, Fan M, Wang L. Over-expression of c-fos mRNA in the hippocampal neurons in Alzheimer's disease. Chin Med J (Engl) 1998, 111(1):35-37.
43. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995, 202(1-2):17-20.
44. Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. NeuroReport 2007, 18(3):297-300. 10.1097/WNR.0b013e3280148e8b, 17314675.
45. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 2008, 105(17):6415-6420. 10.1073/pnas.0710263105, 2359789, 18434550.
46. Bensemain F, Hot D, Ferreira S, Dumont J, Bombois S, Maurage CA, Huot L, Hermant X, Levillain E, Hubans C, et al. Evidence for induction of the ornithine transcarbamylase expression in Alzheimer's disease. Mol Psychiatry 2009, 14(1):106-116. 10.1038/sj.mp.4002089, 17893704.
47. Liu F, Arias-Vasquez A, Sleegers K, Aulchenko YS, Kayser M, Sanchez-Juan P, Feng BJ, Bertoli-Avella AM, van Swieten J, Axenovich TI, et al. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet 2007, 81(1):17-31. 10.1086/518720, 1950931, 17564960.
48. Pérez-Cadahía B, Drobic B, Davie JR. Activation and function of immediate-early genes in the nervous system. Biochem Cell Biol 2011, 89(1):61-73. 10.1139/O10-138, 21326363.
49. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001, 20(19):2438-2452. 10.1038/sj.onc.1204385, 11402339.
50. Tulchinsky E. Fos family members: regulation, structure and role in oncogenic transformation. Histol Histopathol 2000, 15(3):921-928.
51. Song HY, Regnier CH, Kirschning CJ, Goeddel DV, Rothe M. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci U S A 1997, 94(18):9792-9796. 10.1073/pnas.94.18.9792, 23270, 9275204.
52. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001, 24:677-736. 10.1146/annurev.neuro.24.1.677, 2758233, 11520916.
53. Camporeale G, Oommen AM, Griffin JB, Sarath G, Zempleni J. K12-biotinylated histone H4 marks heterochromatin in human lymphoblastoma cells. J Nutr Biochem 2007, 18(11):760-768. 10.1016/j.jnutbio.2006.12.014, 2084386, 17434721.
54. Bao B, Pestinger V, Hassan YI, Borgstahl GE, Kolar C, Zempleni J. Holocarboxylase synthetase is a chromatin protein and interacts directly with histone H3 to mediate biotinylation of K9 and K18. J Nutr Biochem 2011, 22(5):470-475. 10.1016/j.jnutbio.2010.04.001, 2975038, 20688500.
55. Roozendaal B, Phillips RG, Power AE, Brooke SM, Sapolsky RM, McGaugh JL. Memory retrieval impairment induced by hippocampal CA3 lesions is blocked by adrenocortical suppression. Nat Neurosci 2001, 4(12):1169-1171. 10.1038/nn766, 11713467.
56. Kulstad JJ, McMillan PJ, Leverenz JB, Cook DG, Green PS, Peskind ER, Wilkinson CW, Farris W, Mehta PD, Craft S. Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. J Neuropathol Exp Neurol 2005, 64(2):139-146.
57. Griffin W, Stanley L, Ling C, White L, MacLeod V, Perrot L, White C, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989, 86(19):7611-7615. 10.1073/pnas.86.19.7611, 298116, 2529544.
58. Carter C. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int 2007, 50(1):12-38. 10.1016/j.neuint.2006.07.007, 16973241.
59. Dinarello C. Biologic basis for interleukin-1 in disease. Blood 1996, 87(6):2095-2147.
60. Politis A, Olgiati P, Malitas P, Albani D, Signorini A, Polito L, De Mauro S, Zisaki A, Piperi C, Stamouli E, et al. Vitamin B12 levels in Alzheimer's disease: association with clinical features and cytokine production. J Alzheimers Dis 2010, 19(2):481-488.
61. Spulber S, Bartfai T, Schultzberg M. IL-1/IL-1ra balance in the brain revisited - evidence from transgenic mouse models. Brain Behav Immun 2009, 23(5):573-579. 10.1016/j.bbi.2009.02.015, 19258032.
62. Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 2002, 82(6):1311-1329. 10.1046/j.1471-4159.2002.01091.x, 12354279.
63. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev 2005, 48(1):16-42. 10.1016/j.brainresrev.2004.07.021, 15708626.
64. Fujikawa M, Katagiri T, Tugores A, Nakamura Y, Ishikawa F. ESE-3, an Ets family transcription factor, is up-regulated in cellular senescence. Cancer Sci 2007, 98(9):1468-1475. 10.1111/j.1349-7006.2007.00543.x, 17627613.
65. Dezor M, Dorszewska J, Florczak J, Kempisty B, Jaroszewska-Kolecka J, Rozycka A, Polrolniczak A, Bugaj R, Jagodzinski PP, Kozubski W. Expression of 8-oxoguanine DNA glycosylase 1 (OGG1) and the level of p53 and TNF-alphalpha proteins in peripheral lymphocytes of patients with Alzheimer's disease. Folia Neuropathol 2011, 49(2):123-131.
66. de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 2006, 9(2):167-181.
67. Smith-Swintosky VL, Pettigrew LC, Craddock SD, Culwell AR, Rydel RE, Mattson MP. Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J Neurochem 1994, 63(2):781-784.
68. Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S, Kimura J. Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun 1991, 181(1):265-271. 10.1016/S0006-291X(05)81412-3, 1958195.
69. Walsh DM, Selkoe DJ. Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease. Neuron 2004, 44(1):181-193. 10.1016/j.neuron.2004.09.010, 15450169.
70. Barger SW, Mattson MP. Participation of gene expression in the protection against amyloid beta-peptide toxicity by the beta-amyloid precursor protein. Ann N Y Acad Sci 1996, 777:303-309. 10.1111/j.1749-6632.1996.tb34437.x, 8624104.
71. Barger SW, Mattson MP. Induction of neuroprotective kappa B-dependent transcription by secreted forms of the Alzheimer's beta-amyloid precursor. Brain Res Mol Brain Res 1996, 40(1):116-126. 10.1016/0169-328X(96)00036-8, 8840019.
72. Guo Q, Robinson N, Mattson MP. Secreted beta-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-kappaB and stabilization of calcium homeostasis. J Biol Chem 1998, 273(20):12341-12351. 10.1074/jbc.273.20.12341, 9575187.
73. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004, 25(6):280-288. 10.1016/j.it.2004.03.008, 15145317.
74. Chami L, Buggia-Prevot V, Duplan E, Delprete D, Chami M, Peyron JF, Checler F. Nuclear Factor-kappaB Regulates betaAPP and beta- and gamma-Secretases Differently at Physiological and Supraphysiological Abeta Concentrations. J Biol Chem 2012, 287(29):24573-24584. 10.1074/jbc.M111.333054, 22654105.
75. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 2008, 14(1):27-41.
76. Lukiw WJ, Zhao Y, Cui JG. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 2008, 283(46):31315-31322. 10.1074/jbc.M805371200, 2581572, 18801740.
77. Routtenberg A, Rekart JL. Post-translational protein modification as the substrate for long-lasting memory. Trends Neurosci 2005, 28(1):12-19. 10.1016/j.tins.2004.11.006, 15626492.
78. Sacktor TC. How does PKMzeta maintain long-term memory?. Nat Rev Neurosci 2011, 12(1):9-15.
79. Maccecchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig NH. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry 2012, 83(9):894-902. 10.1136/jnnp-2012-302589, 3415310, 22791904.
80. Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Moller HJ, Hampel H, Davidsson P, et al. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol 2003, 183(1):74-80. 10.1016/S0014-4886(03)00027-X, 12957490.
81. Wu G, Sankaranarayanan S, Hsieh SH, Simon AJ, Savage MJ. Decrease in brain soluble amyloid precursor protein beta (sAPPbeta) in Alzheimer's disease cortex. J Neurosci Res 2011, 89(6):822-832. 10.1002/jnr.22618, 21433051.
82. Freude KK, Penjwini M, Davis JL, Laferla FM, Blurton-Jones M. Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J Biol Chem 2011, 286(27):24264-24274. 10.1074/jbc.M111.227421, 3129207, 21606494.
83. Laplagne DA, Esposito MS, Piatti VC, Morgenstern NA, Zhao C, van Praag H, Gage FH, Schinder AF. Functional convergence of neurons generated in the developing and adult hippocampus. PLoS Biol 2006, 4(12):e409. 10.1371/journal.pbio.0040409, 1637132, 17121455.
84. Dhandapani KM, Hadman M, De Sevilla L, Wade MF, Mahesh VB, Brann DW. Astrocyte protection of neurons: role of transforming growth factor-beta signaling via a c-Jun-AP-1 protective pathway. J Biol Chem 2003, 278(44):43329-43339. 10.1074/jbc.M305835200, 12888549.
85. Kamphuis W, Dijk F, van Soest S, Bergen AA. Global gene expression profiling of ischemic preconditioning in the rat retina. Mol Vis 2007, 13:1020-1030. 2776543, 17653046.
86. Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 1991, 37(2):173-182. 10.1016/0165-0270(91)90128-M, 1715499.
87. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M, Ragg T. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006, 7:3. 10.1186/1471-2199-7-3, 1413964, 16448564.
88. Copois V, Bibeau F, Bascoul-Mollevi C, Salvetat N, Chalbos P, Bareil C, Candeil L, Fraslon C, Conseiller E, Granci V, et al. Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality. J Biotechnol 2007, 127(4):549-559. 10.1016/j.jbiotec.2006.07.032, 16945445.
89. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article3.
90. Dalman MR, Deeter A, Nimishakavi G, Duan ZH. Fold change and p-value cutoffs significantly alter microarray interpretations. BMC Bioinforma 2012, 13(Suppl 2):S11.
91. van Iterson M, Boer JM, Menezes RX. Filtering. FDR and power. BMC Bioinforma 2010, 11:450.
92. Plaisier CL, Bare JC, Baliga NS. miRvestigator: web application to identify miRNAs responsible for co-regulated gene expression patterns discovered through transcriptome profiling. Nucleic Acids Res 2011, 39(Web Server issue):W125-W131. 3125776, 21602264.
93. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4(1):44-57.
94. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 1999, 270(1):41-49. 10.1006/abio.1999.4085, 10328763.
95. Pernot F, Dorandeu F, Beaup C, Peinnequin A. Selection of reference genes for real-time quantitative reverse transcription-polymerase chain reaction in hippocampal structure in a murine model of temporal lobe epilepsy with focal seizures. J Neurosci Res 2010, 88(5):1000-1008.
96. Santos AR, Duarte CB. Validation of internal control genes for expression studies: effects of the neurotrophin BDNF on hippocampal neurons. J Neurosci Res 2008, 86(16):3684-3692. 10.1002/jnr.21796, 18655199.
97. Hoffmann J, Pietrzik CU, Kummer MP, Twiesselmann C, Bauer C, Herzog V. Binding and selective detection of the secretory N-terminal domain of the alzheimer amyloid precursor protein on cell surfaces. J Histochem Cytochem 1999, 47(3):373-382. 10.1177/002215549904700311, 10026239.